Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Novo Nordisk's Ozempic was first, but it was used off-label as a weight-loss drug, and had only initially been approved as a diabetes treatment and kidney disease treatment. It's easy to believe ...

The first diabetes and obesity pill that is similar to Ozempic — but in tablet form — may actually outperform the popular ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

As more people resort to a new generation of drugs to achieve the perfect body, Leah Hardy examines the latest warnings over ...

Novo Nordisk ... and Ozempic, as we could argue that Eli Lilly's products are a little better. And Kisunla could become a blockbuster and a big success in treating Alzheimer's disease.

They have the potential to have so many positive effects on our lives, from treating Alzheimer’s disease and addiction to ... in and sales skyrocketed. Deboki: Ozempic is now a bona fide blockbuster.